AZ’s Upbeat Pipeline Message Tarnished By Federal Probes, Poor Sales
This article was originally published in The Pink Sheet Daily
AstraZeneca highlighted pipeline progress during its quarterly earnings call, but remained on the defensive as analysts questioned two newly disclosed U.S. federal inquiries and the promotion of Marc Dunoyer to CFO, as the Big Pharma struggles with falling sales and profits.
You may also be interested in...
Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability
AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.
Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.